← Back to All US Stocks

NTRBW Stock Analysis 2026 - NutriBand Inc. AI Rating

NTRBW Nasdaq Orthopedic, Prosthetic & Surgical Appliances & Supplies NV CIK: 0001676047
Recently Updated • Analysis: Apr 3, 2026 • SEC Data: 2025-10-31
STRONG SELL
95% Conf
Pending
Analysis scheduled

📊 NTRBW Key Takeaways

Revenue: $1.6M
Net Margin: -443.9%
Free Cash Flow: $-4.4M
Current Ratio: 7.53x
Debt/Equity: 0.00x
EPS: $-2.54
AI Rating: STRONG SELL with 95% confidence

Is NTRBW a Good Investment? Thesis Analysis

Claude

NutriBand Inc. is a fundamentally distressed company burning cash at an unsustainable rate with minimal revenue generation. Despite holding $5.3M in cash, operating losses of $7.3M per period combined with negative operating cash flow of $4.4M indicate the company is rapidly consuming its liquidity cushion with no clear path to profitability.

Why Buy NTRBW? Key Strengths

Claude
  • + Strong liquidity position with $5.3M cash representing 63% of total assets
  • + Minimal debt burden with only $1.8K long-term debt and 0.00x debt-to-equity ratio
  • + Low current liabilities relative to liquid assets providing short-term solvency

NTRBW Investment Risks to Consider

Claude
  • ! Severe operating losses of $7.3M against $1.6M revenue, indicating fundamental business model failure
  • ! Negative operating cash flow of $4.4M per period means company will deplete cash reserves in approximately 1.2 periods at current burn rate
  • ! Revenue stagnation with 0.0% YoY growth while operating expenses remain massive, showing no operational leverage or path to scaling
  • ! Negative ROE of -96.2% and ROA of -86.3% demonstrate value destruction across all invested capital
  • ! Operating margin of -446% and net margin of -443.9% indicate the company loses $4.46 for every dollar of revenue

Key Metrics to Watch

Claude
  • * Quarterly cash position and runway remaining at current burn rate
  • * Revenue trends and new product launch success in orthopedic appliances sector
  • * Operating expense reduction initiatives and path to operating cash flow positivity

NTRBW Financial Metrics

Revenue
$1.6M
Net Income
$-7.3M
EPS (Diluted)
$-2.54
Free Cash Flow
$-4.4M
Total Assets
$8.4M
Cash Position
$5.3M

💡 AI Analyst Insight

Strong liquidity with a 7.53x current ratio provides a solid financial cushion.

NTRBW Profitability Ratios

Gross Margin 29.2%
Operating Margin -446.0%
Net Margin -443.9%
ROE -96.2%
ROA -86.3%
FCF Margin -269.5%

NTRBW vs Default Sector

How NutriBand Inc. compares to Default sector averages

Net Margin
NTRBW -443.9%
vs
Sector Avg 12.0%
NTRBW Sector
ROE
NTRBW -96.2%
vs
Sector Avg 15.0%
NTRBW Sector
Current Ratio
NTRBW 7.5x
vs
Sector Avg 1.8x
NTRBW Sector
Debt/Equity
NTRBW 0.0x
vs
Sector Avg 0.7x
NTRBW Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is NTRBW Overvalued or Undervalued?

Based on fundamental analysis, NutriBand Inc. has mixed fundamental signals relative to the Default sector in 2026.

Return on Equity
-96.2%
Sector avg: 15%
Net Profit Margin
-443.9%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.00x
Sector avg: 0.7x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

NTRBW Balance Sheet & Liquidity

Current Ratio
7.53x
Quick Ratio
7.35x
Debt/Equity
0.00x
Debt/Assets
10.3%
Interest Coverage
-424.22x
Long-term Debt
$1.8K

NTRBW 5-Year Financial Trend & Growth Analysis

NTRBW 5-year financial data: Year 2022: Revenue $1.2M, Net Income -$2.9M, EPS N/A. Year 2023: Revenue $1.8M, Net Income -$6.2M, EPS $-0.80. Year 2024: Revenue $2.1M, Net Income -$4.5M, EPS $-0.53. Year 2025: Revenue $2.1M, Net Income -$5.5M, EPS $-0.69.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: NutriBand Inc.'s revenue has grown significantly by 81% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.69 indicates the company is currently unprofitable.

NTRBW Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-269.5%
Free cash flow / Revenue

NTRBW Quarterly Performance

Quarterly financial performance data for NutriBand Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2026 $346.1K -$1.4M $-0.12
Q2 2026 $442.8K -$1.7M $-0.15
Q1 2026 $408.5K -$1.4M $-0.12
Q3 2025 $427.8K -$1.4M $-0.12
Q1 2025 $408.5K -$1.0M $-0.13
Q3 2024 $427.8K -$1.1M $-0.14
Q2 2024 $442.8K -$829.2K $-0.11
Q2 2023 $456.1K -$829.2K $-0.11

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

NTRBW Capital Allocation

Operating Cash Flow
-$4.4M
Cash generated from operations
Capital Expenditures
$5.3K
Investment in assets
Dividends
None
No dividend program

NTRBW SEC 10-K & 10-Q Filing Analysis

Access official SEC EDGAR filings for NutriBand Inc. (CIK: 0001676047)

📋 Recent SEC Filings

Date Form Document Action
Feb 13, 2026 8-K ea0277156-8k_nutriband.htm View →
Feb 3, 2026 8-K ea0275277-8k_nutriband.htm View →
Dec 30, 2025 8-K ea0271298-8k_nutriband.htm View →
Dec 19, 2025 DEF 14A ea0267930-01.htm View →
Dec 11, 2025 10-Q ea0268722-10q_nutriband.htm View →

Frequently Asked Questions about NTRBW

What is the AI rating for NTRBW?

NutriBand Inc. (NTRBW) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.

What are NTRBW's key strengths?

Claude: Strong liquidity position with $5.3M cash representing 63% of total assets. Minimal debt burden with only $1.8K long-term debt and 0.00x debt-to-equity ratio.

What are the risks of investing in NTRBW?

Claude: Severe operating losses of $7.3M against $1.6M revenue, indicating fundamental business model failure. Negative operating cash flow of $4.4M per period means company will deplete cash reserves in approximately 1.2 periods at current burn rate.

What is NTRBW's revenue and growth?

NutriBand Inc. reported revenue of $1.6M.

Does NTRBW pay dividends?

NutriBand Inc. does not currently pay dividends.

Where can I find NTRBW SEC filings?

Official SEC filings for NutriBand Inc. (CIK: 0001676047) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is NTRBW's EPS?

NutriBand Inc. has a diluted EPS of $-2.54.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is NTRBW a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, NutriBand Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is NTRBW stock overvalued or undervalued?

Valuation metrics for NTRBW: ROE of -96.2% (sector avg: 15%), net margin of -443.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy NTRBW stock in 2026?

Our dual AI analysis gives NutriBand Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is NTRBW's free cash flow?

NutriBand Inc.'s operating cash flow is $-4.4M, with capital expenditures of $5.3K. FCF margin is -269.5%.

How does NTRBW compare to other Default stocks?

Vs Default sector averages: Net margin -443.9% (avg: 12%), ROE -96.2% (avg: 15%), current ratio 7.53 (avg: 1.8).

Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 3, 2026 | Data as of: 2025-10-31 | Powered by Claude AI